OS Therapies Inc Logo

OS Therapies Inc

Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.

OSTX | US

Overview

Corporate Details

ISIN(s):
US68764Y2072
LEI:
Country:
United States of America
Address:
15825 SHADY GROVE ROAD, 20850 ROCKVILLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

OS Therapies Inc. is a clinical-stage immunotherapy company focused on the development and commercialization of treatments for cancer. The company develops therapies designed to activate the patient's immune system to target and kill cancers expressing the HER2 protein. Its lead candidate, OST-HER2, is a cancer vaccine primarily targeting Osteosarcoma, a type of bone cancer with a significant unmet medical need in both pediatric and adult patients. OS Therapies is also planning to expand its therapeutic development into other HER2-expressing solid tumors, including breast, colorectal, esophageal, lung, and ovarian cancers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all OS Therapies Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OS Therapies Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OS Therapies Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France
ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden
ABLI
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France
AB
ACADIA PHARMACEUTICALS INC Logo
Develops and commercializes innovative therapies for CNS disorders and rare diseases.
United States of America
ACAD
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM

Talk to a Data Expert

Have a question? We'll get back to you promptly.